Compounds > substance p
Page last updated: 2024-08-23

substance p and aprepitant

substance p has been researched along with aprepitant in 81 studies

Research

Studies (81)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's7 (8.64)18.2507
2000's24 (29.63)29.6817
2010's35 (43.21)24.3611
2020's15 (18.52)2.80

Authors

AuthorsStudies
Bissantz, C; Bohnert, C; Hoffmann, T; Malherbe, P; Marcuz, A; Schnider, P1
Carlson, EJ; Carman, J; Cascieri, MA; Chicchi, GG; Cutler, N; Feighner, J; Hale, JJ; Hargreaves, RJ; Harrison, T; Hefti, F; Hewson, L; Hill, RG; Kramer, MS; Liu, G; MacCoss, M; Mills, SG; Reines, SA; Rupniak, NM; Sadowski, S; Scolnick, EM; Shrivastava, R; Smith, D; Snavely, D; Sramek, JJ; Swain, CJ; Williams, AR; Wyatt-Knowles, E1
Wahlestedt, C1
Nutt, D1
Enserink, M1
Ferro, CJ; Gertz, BJ; Lowry, RC; Majumdar, A; Newby, DE; Sciberras, DG; Sommerville, D; Webb, DJ1
O'Sullivan, GC; Shanahan, F1
Berger, M; Fiebich, BL; Lieb, K1
DeVane, CL1
Rupniak, NM1
Berger, M; Fiebich, BL; Herpfer, I; Lieb, K1
Hargreaves, R1
Krishnan, R; Ranga, K1
Aapro, M; Carides, AD; Evans, JK; Hargreaves, R; Hesketh, PJ; Horgan, KJ; Naylor, RJ; Tattersall, FD; Van Belle, S1
Stahl, SM1
Olver, IN1
Blier, P; Gobbi, G; Haddjeri, N; Hen, R; Mathew, G; Santarelli, L1
Chavez-Eng, CM; Constanzer, ML; Dru, J; Kline, WF; Matuszewski, BK1
Batra, U; Chen, C; Hettrick, L; Higgins, R; Kwei, G; Landis, E; Loper, A; Lynn, K; Novak, L; Shelukar, S; Storey, D; Thompson, K; Wu, Y1
Prommer, E1
Ball, W; Beebe, K; Hargreaves, R; Hietala, J; Keller, M; Lines, C; Liu, G; Montgomery, S; Morrison, M; Reines, S; Snavely, D1
Ballard, TM; Haman, M; Higgins, GA; Woolley, ML1
Longo, K; Lowe, J; Spencer, R1
Andreetta, F; Carletti, R; Corsi, M; Griffante, C1
Green, C; Hewlett, E; Hughes, M; Padgett, D; Schwartz, L; Tessier, J; Zhao, W1
Nieber, K; Schoppmeyer, K1
Chandra, P; Cowen, J; Hafizi, S1
Asai, H; Ishii, T; Kiuchi, S; Nagasaki, M; Okamoto, M; Saito, A; Taniguchi, H; Watanabe, Y1
Douglas, SD1
D'Souza, M; Garza, A; Martin, P; Mastrangelo, MA; Robinson, P; Tweardy, D1
Durkin, S; Jacquet, A; Nordquist, RE; Spooren, W1
Muñoz, M; Rosso, M1
Coveñas, R; González-Ortega, A; Muñoz, M; Robles-Frias, MJ; Rosso, M; Rosso, R; Salinas-Martín, MV1
Douglas, SD; Manak, MM; Meshki, J; Moshkoff, DA; Nguyen, LT; Tebas, P; Tuluc, F1
Coveñas, R; González-Ortega, A; Muñoz, M1
Endo, M; Murakami, H; Nakamura, Y; Takahashi, T; Tsuya, A; Yamamoto, N1
Buhren, BA; Gerber, PA; Homey, B1
Egashira, N; Kawashiri, T; Kurobe, K; Matsushita, N; Oishi, R; Tatsushima, Y; Yano, T1
Heilig, M; Henderson, P; Lofwall, MR; Nuzzo, PA; Walsh, SL1
Carranza, A; Coveñas, R; González-Ortega, A; Muñoz, M; Robles-Frias, MJ; Rosso, M; Salinas-Martín, MV1
Bazakas, A; Ladizinski, B; Olsen, EA1
Douglas, SD; Meshki, J; Schwartz, L; Spitsin, SV; Tuluc, F; Wolfe, JH1
Douglas, SD; Meshki, J; Ping Lai, J; Spitsin, S; Tuluc, F; Tustin Iii, R1
Berger, M; de Agustín Asencio, JC; Garnier, A; Ilmer, M; Kappler, R; Muñoz, M; Neth, O; Salinas-Martín, MV; von Schweinitz, D1
Edvinsson, L; Wallengren, J1
Chang, AS; Gifford, AH; Gilani, A; Hilton, J; Kraemer, WJ; Kupchak, BR; Mahler, DA; Waterman, LA1
Asano, K; Ito, Y; Kim, S; Ogura, Y; Tasaka, A; Yamamoto, K; Yamatodani, A1
Ghabriel, MN; Harford-Wright, E; Lewis, KM; Vink, R1
Boland, JW; Kyeremateng, S1
Almendro, V; Carranza, A; Coveñas, R; Garcia-Recio, S; González-Ortega, A; Muñoz, M; Salinas-Martín, MV1
Chmielinska, JJ; Kramer, JH; Mak, IT; Spurney, CF; Weglicki, WB1
Bettelini, L; Corsi, M; Costantini, VJ; Dünstl, G; Gerrard, P; Zonzini, L1
Luger, TA; Ständer, S1
Barrett, JS; Catalano, R; Douglas, SD; Elci, O; Evans, DL; Kim, D; Korelitz, JJ; Spitsin, S; Tebas, P; Tuluc, F; Wagner, W; Winters, A1
Covenas, R; Esteban, F; Munoz, M; Redondo, M1
Alt, E; Berger, M; Garnier, A; Hubertus, J; Ilmer, M; Kappler, R; von Schweinitz, D; Vykoukal, J1
Ishimaru, Y; Narahara, S; Sakamoto, A; Sugiuchi, H; Yamaguchi, R; Yamaguchi, Y; Yamamoto, T1
Baker, K; Barrett, JS; Barrett, K; Douglas, SD; Evans, DL; Lackner, A; Moorthy, G; Spitsin, S; Tulic, F; Winters, A1
Chau, NG; Kupper, TS; LeBoeuf, NR; Song, JS; Tawa, M1
Eirefelt, S; Hawro, T; Hoey, G; Koopmann, W; Maurer, M; Metz, M; Ohanyan, T; Schoepke, N1
de Lange, ECM; de Witte, WEA; Gul, S; Heitman, LH; IJzerman, AP; Kuzikov, M; Nederpelt, I; Schnider, P; Tuijt, B1
Honda, T; Kabashima, K; Kitayama, N; Nakashima, C; Nonomura, Y; Otsuka, A; Usui, K; Wong, LS; Yamamoto, Y1
Bradley, M; Hall, MA; Heilborn, J; Holmberg, J; Holst, M; Killasli, H; Lönndahl, L; Nordlind, K; Theodorsson, E1
Baird, NL; Blackmon, AM; Bubak, AN; Cohrs, RJ; Como, CN; Frietze, S; Jones, D; Mescher, T; Nagel, MA; Paucek, P1
Bonci, A; Demarest, TG; Francis, TC; Shen, H; Yano, H1
Afshari, AR; Hashemy, SI; Javid, H; Mashkani, B; Mohammadi, F1
Boutelet, I; Boyer, HG; Cailleux, AF; Cauliez, B; Cherifi, S; Defortescu, G; Dubessy, C; Duparc, C; Gobet, F; Guiheneuf, C; Lefebvre, H; Lopez, AG; Louiset, E; Ménard, JF; Wils, J1
Lipiński, P; Matalińska, J; Misicka, A; Świć, A1
Darban, RA; Ebrahimi, S; Hashemy, SI; Mozafari, M1
Adachi, N; Ishikawa, M; Kanemitsu, M; Miyaki, S; Nakasa, T; Nekomoto, A; Shirakawa, Y; Yimiti, D1
Aghaee-Bakhtiari, SH; Ebrahimi, S; Hashemy, SI; Mirzavi, F1
Assaran Darban, R; Hashemy, SI; Javid, H; Rezaei, S1
Firoozrai, M; Golestaneh, M; Hashemy, SI; Javid, H1
Coveñas, R; Muñoz, M; Robinson, P1
Afshari, AR; AlAlikhan, A; Ghahremanloo, A; Hashemy, SI; Javid, H; Momen Razmgah, M1
AlAlikhan, A; Ebrahimi, S; Ghahremanloo, A; Hashemy, SI; Javid, H1
Becerik, Ç; Karaca, ÇT; Kul, S; Özcan, Z; Toros, SZ1
Bunnett, NW; Gmeiner, P; Hegron, A; Huebner, H; Imlach, WL; Jensen, DD; Latorre, R; Peach, CJ; Poole, DP; Rientjes, J; Schmidt, BL; Seemann, P; Teng, S; Thomsen, ARB; Tonello, R; Veldhuis, NA; Weikert, D1
Assaran Darban, R; Hashemy, SI; Jafarinezhad, S; Javid, H1
Coveñas, R; Muñoz, M; Robinson, P; Rodríguez, FD1

Reviews

13 review(s) available for substance p and aprepitant

ArticleYear
[Substance P receptor antagonists--a new antidepressive and anxiolytic mechanism?].
    Der Nervenarzt, 2000, Volume: 71, Issue:9

    Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Aprepitant; Depression; Humans; Morpholines; Neurokinin-1 Receptor Antagonists; Substance P

2000
Substance P: a new era, a new role.
    Pharmacotherapy, 2001, Volume: 21, Issue:9

    Topics: Animals; Antidepressive Agents, Second-Generation; Aprepitant; Depression; Humans; Morpholines; Neuropeptides; Pain; Stress, Psychological; Substance P; Synaptic Transmission

2001
Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists.
    Current opinion in investigational drugs (London, England : 2000), 2002, Volume: 3, Issue:2

    Topics: Animals; Antidepressive Agents; Aprepitant; Clinical Trials as Topic; Depressive Disorder; Drug Evaluation, Preclinical; Humans; Morpholines; Neurokinin-1 Receptor Antagonists; Stress, Physiological; Substance P; Treatment Outcome

2002
Imaging substance P receptors (NK1) in the living human brain using positron emission tomography.
    The Journal of clinical psychiatry, 2002, Volume: 63 Suppl 11

    Topics: Animals; Aprepitant; Autoradiography; Brain; Brain Mapping; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Guinea Pigs; Humans; Iodine Radioisotopes; Macaca mulatta; Morpholines; Neurokinin-1 Receptor Antagonists; Receptors, Neurokinin-1; Substance P; Tomography, Emission-Computed

2002
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
    European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:8

    Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Granisetron; Humans; Morpholines; Neoplasms; Neurokinin-1 Receptor Antagonists; Neurotransmitter Agents; Ondansetron; Prodrugs; Serotonin; Serotonin Antagonists; Substance P; Vomiting

2003
Aprepitant in antiemetic combinations to prevent chemotherapy-induced nausea and vomiting.
    International journal of clinical practice, 2004, Volume: 58, Issue:2

    Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Male; Morpholines; Substance P; Tomography, Emission-Computed; Vomiting

2004
Aprepitant (EMEND): the role of substance P in nausea and vomiting.
    Journal of pain & palliative care pharmacotherapy, 2005, Volume: 19, Issue:3

    Topics: Animals; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Clinical Trials as Topic; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Liver; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Receptors, Neurokinin-1; Substance P; Vomiting

2005
[Prevention of nausea and vomiting. Aprepitant, the first therapeutic acting NK-1 receptor antagonist].
    Pharmazie in unserer Zeit, 2007, Volume: 36, Issue:5

    Topics: Animals; Antiemetics; Antineoplastic Agents; Aprepitant; Humans; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Substance P; Vomiting

2007
NK-1 Antagonists and Itch.
    Handbook of experimental pharmacology, 2015, Volume: 226

    Topics: Animals; Aprepitant; Humans; Morpholines; Pruritus; Receptors, Neurokinin-1; Substance P

2015
The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.
    Journal of biosciences, 2015, Volume: 40, Issue:2

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Aprepitant; Cell Movement; Cell Proliferation; Emotions; Humans; Inflammation; Morpholines; Neoplasms; Neovascularization, Pathologic; Neurokinin-1 Receptor Antagonists; Receptors, Neurokinin-1; Substance P

2015
Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature.
    BMC cancer, 2017, 03-16, Volume: 17, Issue:1

    Topics: Adult; Aged; Aprepitant; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Morpholines; Neurokinin-1 Receptor Antagonists; Protein Binding; Pruritus; Substance P

2017
Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy?
    Current medicinal chemistry, 2023, Volume: 30, Issue:16

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Chemoradiotherapy; Drug Repositioning; Humans; Neoplasms; Neurokinin-1 Receptor Antagonists; Substance P

2023
The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
    International journal of molecular sciences, 2023, Nov-03, Volume: 24, Issue:21

    Topics: Antineoplastic Agents; Aprepitant; Drug Repositioning; Humans; Neoplasms; Neurokinin-1 Receptor Antagonists; Quality of Life; Receptors, Neurokinin-1; Substance P

2023

Trials

12 trial(s) available for substance p and aprepitant

ArticleYear
Distinct mechanism for antidepressant activity by blockade of central substance P receptors.
    Science (New York, N.Y.), 1998, Sep-11, Volume: 281, Issue:5383

    Topics: Adolescent; Adult; Aged; Amygdala; Animals; Antidepressive Agents, Second-Generation; Aprepitant; Behavior, Animal; Brain; Depressive Disorder; Female; Gerbillinae; Guinea Pigs; Humans; Male; Middle Aged; Morpholines; Neurokinin-1 Receptor Antagonists; Norepinephrine; Paroxetine; Receptors, Neurokinin-1; Serotonin; Stress, Psychological; Substance P; Vocalization, Animal

1998
Substance-P antagonists: a new treatment for depression?
    Lancet (London, England), 1998, Nov-21, Volume: 352, Issue:9141

    Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Aprepitant; Depressive Disorder; Double-Blind Method; Humans; Morpholines; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Substance P

1998
Substance P-induced vasodilatation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man.
    British journal of clinical pharmacology, 1999, Volume: 48, Issue:3

    Topics: Acetals; Antiemetics; Aprepitant; Blood Pressure; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Forearm; Humans; Male; Morpholines; Neurokinin-1 Receptor Antagonists; Receptors, Neurokinin-1; Regional Blood Flow; Substance P; Vasodilation

1999
Clinical experience with substance P receptor (NK1) antagonists in depression.
    The Journal of clinical psychiatry, 2002, Volume: 63 Suppl 11

    Topics: Antidepressive Agents; Anxiety Disorders; Aprepitant; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Ethers; Female; Humans; Hydrocarbons, Fluorinated; Male; Morpholines; Neurokinin-1 Receptor Antagonists; Paroxetine; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Substance P; Treatment Outcome

2002
Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder.
    Biological psychiatry, 2006, Feb-01, Volume: 59, Issue:3

    Topics: Adult; Antidepressive Agents; Aprepitant; Brain; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Morpholines; Neurokinin-1 Receptor Antagonists; Personality Inventory; Positron-Emission Tomography; Reproducibility of Results; Substance P; Treatment Outcome

2006
Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:3

    Topics: Adult; Aged; Anti-Inflammatory Agents; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Dexamethasone; Drug Therapy, Combination; Female; Granisetron; Humans; Immunoenzyme Techniques; Japan; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Morpholines; Nausea; Small Cell Lung Carcinoma; Substance P; Vomiting; Young Adult

2011
Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers.
    Addiction biology, 2013, Volume: 18, Issue:2

    Topics: Administration, Intranasal; Adult; Analgesics, Opioid; Analysis of Variance; Animals; Antiemetics; Aprepitant; Area Under Curve; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Drug Tolerance; Female; Humans; Male; Mice; Mice, Knockout; Morpholines; Neurokinin-1 Receptor Antagonists; Opioid-Related Disorders; Oxycodone; Placebos; Psychomotor Performance; Receptors, Neurokinin-1; Reinforcement, Psychology; Substance P; Time Factors

2013
Antagonism of substance P and perception of breathlessness in patients with chronic obstructive pulmonary disease.
    Respiratory physiology & neurobiology, 2014, Jun-01, Volume: 196

    Topics: Aged; Aprepitant; beta-Endorphin; Double-Blind Method; Dyspnea; Female; Humans; Male; Morpholines; Naloxone; Narcotic Antagonists; Neurokinin-1 Receptor Antagonists; Perception; Pulmonary Disease, Chronic Obstructive; Respiration; Substance P; Time Factors; Treatment Outcome

2014
Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults.
    AIDS (London, England), 2015, May-15, Volume: 29, Issue:8

    Topics: Adult; Anti-HIV Agents; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Aprepitant; Biomarkers; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Morpholines; Neurokinin-1 Receptor Antagonists; Programmed Cell Death 1 Receptor; Prospective Studies; Receptors, Cell Surface; Receptors, Neurokinin-1; Substance P; Young Adult

2015
Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant.
    Acta dermato-venereologica, 2018, Jan-12, Volume: 98, Issue:1

    Topics: Administration, Cutaneous; Aged; Aprepitant; Case-Control Studies; Chronic Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Morpholines; Neurokinin-1 Receptor Antagonists; Proof of Concept Study; Prospective Studies; Prurigo; Pruritus; Receptors, Neurokinin-1; Severity of Illness Index; Substance P; Visual Analog Scale

2018
Substance P Antagonist Aprepitant Shows no Additive Effect Compared with Standardized Topical Treatment Alone in Patients with Atopic Dermatitis.
    Acta dermato-venereologica, 2018, Mar-13, Volume: 98, Issue:3

    Topics: Administration, Cutaneous; Adult; Antipruritics; Aprepitant; Dermatitis, Atopic; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Morpholines; Neurokinin-1 Receptor Antagonists; Pruritus; Severity of Illness Index; Skin; Substance P; Sweden; Time Factors; Treatment Outcome; Young Adult

2018
The neuropeptide substance P regulates aldosterone secretion in human adrenals.
    Nature communications, 2020, 05-29, Volume: 11, Issue:1

    Topics: Adolescent; Adrenal Cortex; Adrenal Glands; Adult; Aldosterone; Aprepitant; Cells, Cultured; Humans; Hypoglycemia; Male; Metoclopramide; Mineralocorticoids; Neurokinin-1 Receptor Antagonists; Placebos; Proof of Concept Study; Prospective Studies; Receptors, Neurokinin-1; Substance P; Transaminases; Young Adult

2020

Other Studies

56 other study(ies) available for substance p and aprepitant

ArticleYear
Identification of a crucial amino acid in the helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK₁/NK₃ antagonists.
    Journal of medicinal chemistry, 2012, Jun-14, Volume: 55, Issue:11

    Topics: Amino Acids; Aminopyridines; Benzeneacetamides; HEK293 Cells; Humans; Inositol Phosphates; Models, Molecular; Mutagenesis, Site-Directed; Mutation; Neurokinin-1 Receptor Antagonists; Protein Structure, Secondary; Radioligand Assay; Receptors, Neurokinin-1; Receptors, Neurokinin-3; Stereoisomerism

2012
Reward for persistence in substance P research.
    Science (New York, N.Y.), 1998, Sep-11, Volume: 281, Issue:5383

    Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Aprepitant; Brain; Clinical Trials, Phase II as Topic; Depressive Disorder; Humans; Morpholines; Neurokinin-1 Receptor Antagonists; Substance P

1998
Can the placebo be the cure?
    Science (New York, N.Y.), 1999, Apr-09, Volume: 284, Issue:5412

    Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Aprepitant; Depressive Disorder; Double-Blind Method; Humans; Meta-Analysis as Topic; Monoamine Oxidase Inhibitors; Morpholines; Placebos; Psychopharmacology; Randomized Controlled Trials as Topic; Research Design; Selective Serotonin Reuptake Inhibitors; Substance P

1999
Neurokinin antagonism and chemotherapy-induced emesis.
    The American journal of gastroenterology, 1999, Volume: 94, Issue:11

    Topics: Acetals; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Female; Granisetron; Humans; Male; Morpholines; Multicenter Studies as Topic; Nausea; Neurokinin-1 Receptor Antagonists; Randomized Controlled Trials as Topic; Substance P; Vomiting

1999
MK 869. L 754030, MK 0869.
    Drugs in R&D, 1999, Volume: 2, Issue:4

    Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Clinical Trials, Phase II as Topic; Humans; Morpholines; Neurokinin-1 Receptor Antagonists; Placebos; Randomized Controlled Trials as Topic; Substance P; Vomiting

1999
[Substance P-antagonists as a new class of antidepressant drugs].
    Deutsche medizinische Wochenschrift (1946), 2002, Nov-29, Volume: 127, Issue:48

    Topics: Animals; Antidepressive Agents; Aprepitant; Depression; Double-Blind Method; Humans; Mice; Mice, Knockout; Morpholines; Neurokinin-1 Receptor Antagonists; Placebos; Randomized Controlled Trials as Topic; Rats; Substance P; Time Factors

2002
The ups and downs of novel antiemetic drugs, part 1: substance P, 5-HT, and the neuropharmacology of vomiting.
    The Journal of clinical psychiatry, 2003, Volume: 64, Issue:5

    Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Area Postrema; Brain Stem; Depressive Disorder; Humans; Morpholines; Receptors, Neurokinin-1; Serotonin; Solitary Nucleus; Stress Disorders, Traumatic; Substance P; Vomiting

2003
Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response.
    Journal of psychiatry & neuroscience : JPN, 2004, Volume: 29, Issue:3

    Topics: Adrenergic alpha-Agonists; Animals; Antiemetics; Anxiety; Aprepitant; Autoreceptors; Depressive Disorder, Major; Electrophysiology; Hippocampus; Locus Coeruleus; Mice; Mice, Mutant Strains; Morpholines; Neurokinin-1 Receptor Antagonists; Norepinephrine; Phenylephrine; Photomicrography; Raphe Nuclei; Receptors, Neurokinin-1; Serotonin; Substance P

2004
Determination of a novel substance P inhibitor in human plasma by high-performance liquid chromatography with atmospheric pressure chemical ionization mass spectrometric detection using single and triple quadrupole detectors.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2004, Aug-05, Volume: 807, Issue:2

    Topics: Aprepitant; Atmospheric Pressure; Chromatography, High Pressure Liquid; Humans; Mass Spectrometry; Morpholines; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Substance P

2004
The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human.
    International journal of pharmaceutics, 2004, Nov-05, Volume: 285, Issue:1-2

    Topics: Absorption; Administration, Oral; Animals; Antineoplastic Agents; Aprepitant; Area Under Curve; Biological Availability; Capsules; Chemistry, Pharmaceutical; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dogs; Drug Administration Schedule; Drug Evaluation, Preclinical; Fasting; Food-Drug Interactions; Humans; Male; Models, Animal; Morpholines; Nanostructures; Nausea; Substance P; Tablets; Technology, Pharmaceutical; Upper Gastrointestinal Tract; Vomiting

2004
Investigating the effect of bilateral amygdala lesions on fear conditioning and social interaction in the male Mongolian gerbil.
    Brain research, 2006, Mar-17, Volume: 1078, Issue:1

    Topics: Amygdala; Analysis of Variance; Animals; Aprepitant; Behavior, Animal; Conditioning, Classical; Dose-Response Relationship, Drug; Drug Interactions; Fear; Gerbillinae; Ibotenic Acid; Immobility Response, Tonic; Interpersonal Relations; Male; Morpholines; Motor Activity; Neurokinin-1 Receptor Antagonists; Peptide Fragments; Substance P

2006
What goes around comes around in drug discovery.
    Nature, 2006, Feb-23, Volume: 439, Issue:7079

    Topics: Antiemetics; Aprepitant; Biomedical Research; Drug Industry; History, 20th Century; Morpholines; Substance P

2006
[3H]GR205171 displays similar NK1 receptor binding profile in gerbil and human brain.
    British journal of pharmacology, 2006, Volume: 148, Issue:1

    Topics: Adolescent; Aged, 80 and over; Animals; Aprepitant; Autoradiography; Binding, Competitive; Brain; Female; Gerbillinae; Humans; In Vitro Techniques; Kinetics; Ligands; Male; Middle Aged; Models, Animal; Morpholines; Piperidines; Radioligand Assay; Receptors, Neurokinin-1; Substance P; Tetrazoles; Tritium

2006
Contributions of histamine, prostanoids, and neurokinins to edema elicited by edema toxin from Bacillus anthracis.
    Infection and immunity, 2007, Volume: 75, Issue:4

    Topics: Animals; Antigens, Bacterial; Aprepitant; Bacillus anthracis; Bacterial Toxins; Capillary Permeability; Celecoxib; Cell Degranulation; Cell Line; Disease Models, Animal; Edema; Enzyme Inhibitors; Histamine; Histamine H1 Antagonists; Humans; Indomethacin; Injections, Intradermal; Mast Cells; Morpholines; Neurokinin-1 Receptor Antagonists; Prostaglandin Antagonists; Prostaglandins; Pyrazoles; Pyrilamine; Rabbits; Substance P; Sulfonamides; Tachykinins

2007
Neurokinin-1 receptor antagonists as novel antidepressants: trials and tribulations.
    The British journal of psychiatry : the journal of mental science, 2007, Volume: 191

    Topics: Animals; Antidepressive Agents; Aprepitant; Clinical Trials as Topic; Depressive Disorder; Drug Design; Humans; Models, Animal; Morpholines; Neurokinin-1 Receptor Antagonists; Substance P

2007
Pharmacological characterization of T-2328, 2-fluoro-4'-methoxy-3'-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,1'-biphenyl]-4-carbonitrile dihydrochloride, as a brain-penetrating antagonist of tachykinin NK1 receptor.
    Journal of pharmacological sciences, 2008, Volume: 106, Issue:1

    Topics: Animals; Antiemetics; Antineoplastic Agents; Aprepitant; Binding Sites; Brain; Cell Line, Tumor; CHO Cells; Cisplatin; Cricetinae; Cricetulus; Disease Models, Animal; Dose-Response Relationship, Drug; Ferrets; Gerbillinae; Humans; Kinetics; Male; Morpholines; Motor Activity; Neurokinin-1 Receptor Antagonists; Peptide Fragments; Piperidines; Receptors, Neurokinin-1; Substance P; Transfection; Vomiting

2008
Elevated plasma substance P in sickle cell disease and vaso-occlusive crisis.
    Medical hypotheses, 2008, Volume: 70, Issue:6

    Topics: Anemia, Sickle Cell; Antiemetics; Aprepitant; Clinical Trials, Phase I as Topic; Humans; Models, Immunological; Morpholines; Neurokinin-1 Receptor Antagonists; Pain; Substance P

2008
Substance P receptor antagonism for treatment of cryptosporidiosis in immunosuppressed mice.
    The Journal of parasitology, 2008, Volume: 94, Issue:5

    Topics: Analysis of Variance; Animals; Aprepitant; Cattle; Cryptosporidiosis; Cryptosporidium parvum; Dexamethasone; Disease Models, Animal; Feces; Glucose; Immunosuppressive Agents; Jejunum; Mice; Mice, Inbred C57BL; Microvilli; Morpholines; Neurokinin-1 Receptor Antagonists; Parasite Egg Count; Random Allocation; Substance P; Weight Loss

2008
The tachykinin NK3 receptor agonist senktide induces locomotor activity in male Mongolian gerbils.
    European journal of pharmacology, 2008, Dec-14, Volume: 600, Issue:1-3

    Topics: Animals; Aprepitant; Behavior, Animal; Dose-Response Relationship, Drug; Gerbillinae; Hyperkinesis; Injections, Intraventricular; Male; Models, Animal; Morpholines; Neurokinin-1 Receptor Antagonists; Peptide Fragments; Pharmaceutical Vehicles; Receptors, Neurokinin-3; Species Specificity; Substance P

2008
The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug.
    Investigational new drugs, 2010, Volume: 28, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Aprepitant; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Mitogens; Morpholines; Neurokinin-1 Receptor Antagonists; Substance P

2010
The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines.
    Laboratory investigation; a journal of technical methods and pathology, 2010, Volume: 90, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Aprepitant; Cell Line; Cell Proliferation; Humans; Melanoma; Morpholines; Neurokinin-1 Receptor Antagonists; Receptors, Neurokinin-1; Skin Neoplasms; Substance P

2010
Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals.
    AIDS (London, England), 2010, Nov-27, Volume: 24, Issue:18

    Topics: Anti-HIV Agents; Aprepitant; Blood-Brain Barrier; Cells, Cultured; Central Nervous System Diseases; Drug Interactions; HIV Infections; HIV-1; Humans; Morpholines; Neurokinin-1 Receptor Antagonists; Receptors, Neurokinin-1; Signal Transduction; Substance P

2010
The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines.
    Investigational new drugs, 2012, Volume: 30, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Aprepitant; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Child; Dose-Response Relationship, Drug; Female; Humans; Inhibitory Concentration 50; Morpholines; Neurokinin-1 Receptor Antagonists; Piperidines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Real-Time Polymerase Chain Reaction; Receptors, Neurokinin-1; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Messenger; Substance P; Tryptophan

2012
More on aprepitant for erlotinib-induced pruritus.
    The New England journal of medicine, 2011, 02-03, Volume: 364, Issue:5

    Topics: Antiemetics; Aprepitant; Erlotinib Hydrochloride; Humans; Morpholines; Neurokinin-1 Receptor Antagonists; Off-Label Use; Protein Kinase Inhibitors; Pruritus; Quinazolines; Substance P

2011
Pemirolast reduces cisplatin-induced kaolin intake in rats.
    European journal of pharmacology, 2011, Jul-01, Volume: 661, Issue:1-3

    Topics: Animals; Antineoplastic Agents; Aprepitant; Biological Transport; Body Weight; Cisplatin; Dexamethasone; Eating; Kaolin; Male; Morpholines; Ondansetron; Pyridines; Pyrimidinones; Rats; Substance P

2011
The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists.
    Peptides, 2012, Volume: 38, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Aprepitant; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Morpholines; Neurokinin-1 Receptor Antagonists; Piperidines; Receptors, Neurokinin-1; Structure-Activity Relationship; Substance P; Tryptophan; Tumor Cells, Cultured

2012
Aprepitant: a novel neurokinin-1 receptor/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma.
    Journal of the American Academy of Dermatology, 2012, Volume: 67, Issue:5

    Topics: Aged; Antipruritics; Aprepitant; Drug Therapy, Combination; Female; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, T-Cell, Cutaneous; Morpholines; Neurokinin-1 Receptor Antagonists; Ondansetron; Pain Measurement; Recombinant Proteins; Substance P

2012
Substance P enhances HIV-1 infection in human fetal brain cell cultures expressing full-length neurokinin-1 receptor.
    Journal of neurovirology, 2013, Volume: 19, Issue:3

    Topics: Aprepitant; Brain; Calcium; Electric Impedance; Fetus; Gene Expression; HIV-1; Host-Pathogen Interactions; Humans; Ion Transport; Morpholines; Neurokinin-1 Receptor Antagonists; Neurons; Primary Cell Culture; Receptors, Neurokinin-1; Substance P; Virus Activation

2013
Analog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor.
    Neuroimmunomodulation, 2013, Volume: 20, Issue:5

    Topics: Analgesics; Aprepitant; Calcium; Cell Line; Chemokine CCL2; Cytokines; Dose-Response Relationship, Drug; Drug Interactions; gag Gene Products, Human Immunodeficiency Virus; Gene Expression Regulation; Humans; Macrophages; Morpholines; Neurokinin-1 Receptor Antagonists; NF-kappa B; Receptors, Neurokinin-1; Receptors, Somatostatin; Signal Transduction; Somatostatin; Substance P; Transfection

2013
Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
    Journal of hepatology, 2014, Volume: 60, Issue:5

    Topics: Animals; Apoptosis; Aprepitant; Cell Line, Tumor; Cell Proliferation; Child; Cytostatic Agents; Drug Synergism; Female; Gene Expression; Hep G2 Cells; Hepatoblastoma; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Morpholines; Neovascularization, Pathologic; Neurokinin-1 Receptor Antagonists; Protein Isoforms; Receptors, Neurokinin-1; Substance P; Xenograft Model Antitumor Assays

2014
Topical non-peptide antagonists of sensory neurotransmitters substance P and CGRP do not modify patch test and prick test reactions: a vehicle-controlled, double-blind pilot study.
    Archives of dermatological research, 2014, Volume: 306, Issue:5

    Topics: Adult; Aged; Antipruritics; Aprepitant; Azepines; Calcitonin Gene-Related Peptide; Dermatitis, Contact; Double-Blind Method; Female; Humans; Hypersensitivity, Delayed; Imidazoles; Male; Middle Aged; Morpholines; Nickel; Permeability; Pilot Projects; Pruritus; Skin; Skin Physiological Phenomena; Skin Tests; Substance P; Urticaria; Vasoconstriction; Water Loss, Insensible; Young Adult

2014
Involvement of substance P in the development of cisplatin-induced acute and delayed pica in rats.
    British journal of pharmacology, 2014, Volume: 171, Issue:11

    Topics: Animals; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Eating; Granisetron; Kaolin; Male; Medulla Oblongata; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Pica; Protein Precursors; Rats, Wistar; Receptors, Neurokinin-1; Receptors, Serotonin, 5-HT3; RNA, Messenger; Serotonin Antagonists; Solitary Nucleus; Substance P; Tachykinins

2014
Treatment with the NK1 antagonist emend reduces blood brain barrier dysfunction and edema formation in an experimental model of brain tumors.
    PloS one, 2014, Volume: 9, Issue:5

    Topics: Animals; Aprepitant; Blood-Brain Barrier; Brain Edema; Brain Neoplasms; Disease Models, Animal; Humans; Male; Mice; Morpholines; Neurokinin-1 Receptor Antagonists; Permeability; Receptors, Neurokinin-1; Substance P

2014
Aprepitant for the management of refractory emesis in a patient with a small bowel carcinoid tumor.
    Journal of pain & palliative care pharmacotherapy, 2014, Volume: 28, Issue:2

    Topics: Aged, 80 and over; Antiemetics; Aprepitant; Carcinoid Tumor; Female; Humans; Intestinal Neoplasms; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Serotonin; Serotonin 5-HT3 Receptor Antagonists; Substance P; Treatment Outcome; Vomiting

2014
The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.
    International journal of oncology, 2014, Volume: 45, Issue:4

    Topics: Antineoplastic Agents; Aprepitant; Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; MCF-7 Cells; Morpholines; Neurokinin-1 Receptor Antagonists; Piperidines; Receptors, Neurokinin-1; Substance P; Tryptophan

2014
EGFR-TKI, erlotinib, causes hypomagnesemia, oxidative stress, and cardiac dysfunction: attenuation by NK-1 receptor blockade.
    Journal of cardiovascular pharmacology, 2015, Volume: 65, Issue:1

    Topics: Animals; Aprepitant; Echocardiography; ErbB Receptors; Erlotinib Hydrochloride; Magnesium; Male; Morpholines; Neurokinin-1 Receptor Antagonists; Oxidative Stress; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, Neurokinin-1; Substance P; Ventricular Function, Left

2015
The NK1 receptor antagonist aprepitant attenuates NK1 agonist-induced scratching behaviour in the gerbil after intra-dermal, topical or oral administration.
    Experimental dermatology, 2015, Volume: 24, Issue:4

    Topics: Administration, Oral; Administration, Topical; Animals; Antipruritics; Aprepitant; Disease Models, Animal; Drug Evaluation, Preclinical; Gerbillinae; Humans; Injections, Intradermal; Morpholines; Neurokinin-1 Receptor Antagonists; Peptide Fragments; Pruritus; Receptors, Neurokinin-1; Substance P

2015
Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells.
    International journal of oncology, 2015, Volume: 47, Issue:1

    Topics: Antineoplastic Agents; Aprepitant; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Molecular Targeted Therapy; Morpholines; Neoplastic Stem Cells; Neurokinin-1 Receptor Antagonists; Receptors, Neurokinin-1; Substance P; Wnt Signaling Pathway

2015
Substance P enhances tissue factor release from granulocyte-macrophage colony-stimulating factor-dependent macrophages via the p22phox/β-arrestin 2/Rho A signaling pathway.
    Blood cells, molecules & diseases, 2016, Volume: 57

    Topics: Acetophenones; Adipocytes; Amides; Aprepitant; Arrestins; Benzopyrans; beta-Arrestin 2; beta-Arrestins; Dynamins; Free Radical Scavengers; Gene Expression Regulation; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Macrophage Activation; Macrophages; Morpholines; NADPH Oxidases; Neurokinin-1 Receptor Antagonists; Phosphorylcholine; Primary Cell Culture; Protein Kinase Inhibitors; Pyridines; Pyrrolidines; rho-Associated Kinases; RNA, Small Interfering; Signal Transduction; Substance P; Thiocarbamates; Thromboplastin

2016
Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV.
    Journal of translational medicine, 2016, 05-26, Volume: 14, Issue:1

    Topics: Adolescent; Adult; Animals; Anti-Inflammatory Agents; Anxiety; Aprepitant; Chemokines; Female; HIV Infections; Humans; Macaca mulatta; Macrophages; Male; Middle Aged; Monocytes; Morpholines; Neurokinin-1 Receptor Antagonists; Protein Binding; Receptors, Neurokinin-1; Simian Acquired Immunodeficiency Syndrome; Substance P; Viral Load; Virus Replication; Young Adult

2016
From receptor binding kinetics to signal transduction; a missing link in predicting in vivo drug-action.
    Scientific reports, 2017, 10-26, Volume: 7, Issue:1

    Topics: Aprepitant; Cell Line, Tumor; Humans; Kinetics; Neurokinin A; Neurokinin-1 Receptor Antagonists; Pharmaceutical Preparations; Receptors, Neurokinin-1; Signal Transduction; Substance P

2017
TRPA1 channel participates in tacrolimus-induced pruritus in a chronic contact hypersensitivity murine model.
    Journal of dermatological science, 2018, Volume: 89, Issue:2

    Topics: Administration, Cutaneous; Animals; Aprepitant; Behavior, Animal; Calcineurin Inhibitors; Dermatitis, Contact; Disease Models, Animal; Filaggrin Proteins; Ganglia, Spinal; Humans; Intermediate Filament Proteins; Male; Mice; Mice, Inbred BALB C; Mice, Transgenic; Ointments; Oxazolone; Oximes; Pruritus; Skin; Substance P; Tacrolimus; TRPA1 Cation Channel

2018
Varicella Zoster Virus Induces Nuclear Translocation of the Neurokinin-1 Receptor, Promoting Lamellipodia Formation and Viral Spread in Spinal Astrocytes.
    The Journal of infectious diseases, 2018, 09-08, Volume: 218, Issue:8

    Topics: Active Transport, Cell Nucleus; Aprepitant; Astrocytes; Cells, Cultured; Gene Expression Regulation; Herpesvirus 3, Human; Humans; Neurokinin-1 Receptor Antagonists; Protein Isoforms; Pseudopodia; Receptors, Neurokinin-1; Spiro Compounds; Substance P

2018
High-Frequency Activation of Nucleus Accumbens D1-MSNs Drives Excitatory Potentiation on D2-MSNs.
    Neuron, 2019, 08-07, Volume: 103, Issue:3

    Topics: Action Potentials; Animals; Aprepitant; Calcium Signaling; Cholinergic Neurons; Dopaminergic Neurons; Excitatory Postsynaptic Potentials; Interneurons; Long-Term Potentiation; Mice; Mice, Inbred C57BL; Motivation; Neurokinin-1 Receptor Antagonists; Nucleus Accumbens; Photic Stimulation; Piperidines; Receptor, Muscarinic M1; Receptors, AMPA; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Neurokinin-1; Substance P

2019
Substance P accelerates the progression of human esophageal squamous cell carcinoma via MMP-2, MMP-9, VEGF-A, and VEGFR1 overexpression.
    Molecular biology reports, 2020, Volume: 47, Issue:6

    Topics: Apoptosis; Aprepitant; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gene Expression; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neurokinin-1 Receptor Antagonists; Receptors, Neurokinin-1; Signal Transduction; Substance P; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2020
Antiproliferative effects of [D-Pro2, D-Trp7,9]-Substance P and aprepitant on several cancer cell lines and their selectivity in comparison to normal cells.
    Folia neuropathologica, 2020, Volume: 58, Issue:3

    Topics: Aprepitant; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Neurokinin-1 Receptor Antagonists; Substance P

2020
Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
    Molecular biology reports, 2022, Volume: 49, Issue:2

    Topics: Apoptosis; Aprepitant; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neurokinin-1 Receptor Antagonists; Receptors, Neurokinin-1; Signal Transduction; Substance P; Uterine Cervical Neoplasms

2022
Therapeutic effect of targeting Substance P on the progression of osteoarthritis.
    Modern rheumatology, 2022, Oct-15, Volume: 32, Issue:6

    Topics: Animals; Aprepitant; Cartilage, Articular; Disease Models, Animal; Humans; Mice; Osteoarthritis; Phosphates; Substance P; X-Ray Microtomography

2022
SP/NK1R system regulates carcinogenesis in prostate cancer: Shedding light on the antitumoral function of aprepitant.
    Biochimica et biophysica acta. Molecular cell research, 2022, Volume: 1869, Issue:5

    Topics: Animals; Antineoplastic Agents; Aprepitant; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D1; G2 Phase Cell Cycle Checkpoints; Humans; Male; Matrix Metalloproteinases; Mice; Mice, Nude; Prostatic Neoplasms; Protein Isoforms; Proto-Oncogene Proteins c-bcl-2; Receptors, Neurokinin-1; Substance P; Survival Rate; Transplantation, Heterologous

2022
The Therapeutic Potential of Aprepitant in Glioblastoma Cancer Cells through Redox Modification.
    BioMed research international, 2022, Volume: 2022

    Topics: Antioxidants; Aprepitant; Cell Line, Tumor; Glioblastoma; Humans; Neurokinin-1 Receptor Antagonists; Oxidation-Reduction; Reactive Oxygen Species; Receptors, Neurokinin-1; Substance P

2022
The substance P/ neurokinin-1 receptor signaling pathway mediates metastasis in human colorectal SW480 cancer cells.
    Molecular biology reports, 2022, Volume: 49, Issue:6

    Topics: Aprepitant; Colorectal Neoplasms; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neurokinin-1 Receptor Antagonists; Receptors, Neurokinin-1; Signal Transduction; Substance P

2022
The effect of substance P and its specific antagonist (aprepitant) on the expression of MMP-2, MMP-9, VEGF, and VEGFR in ovarian cancer cells.
    Molecular biology reports, 2022, Volume: 49, Issue:10

    Topics: Aprepitant; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Female; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neovascularization, Pathologic; Ovarian Neoplasms; Receptors, Neurokinin-1; Receptors, Vascular Endothelial Growth Factor; RNA, Messenger; Substance P; Vascular Endothelial Growth Factor A

2022
The Effect of Blocking Neurokinin-1 Receptor by Aprepitant on the Inflammatory and Apoptosis Pathways in Human Ovarian Cancer Cells.
    Cell biochemistry and biophysics, 2022, Volume: 80, Issue:4

    Topics: Apoptosis; Aprepitant; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Female; Humans; NF-kappa B; Ovarian Neoplasms; Reactive Oxygen Species; Receptors, Neurokinin-1; Substance P; Tumor Suppressor Protein p53

2022
The Role of Substance P Receptor Antagonists in Allergic Rhinitis: Ovalbumin-Induced Rat Model.
    The Laryngoscope, 2023, Volume: 133, Issue:11

    Topics: Animals; Aprepitant; Disease Models, Animal; Female; Histamine Antagonists; Nasal Mucosa; Neurokinin-1 Receptor Antagonists; Ovalbumin; Rats; Rats, Sprague-Dawley; Rhinitis, Allergic; Substance P

2023
Therapeutic antagonism of the neurokinin 1 receptor in endosomes provides sustained pain relief.
    Proceedings of the National Academy of Sciences of the United States of America, 2023, 05-30, Volume: 120, Issue:22

    Topics: Animals; Aprepitant; Endosomes; Humans; Mice; Pain; Receptors, G-Protein-Coupled; Receptors, Neurokinin-1; Substance P

2023
The SP/NK1R system promotes the proliferation of breast cancer cells through NF-κB-mediated inflammatory responses.
    Cell biochemistry and biophysics, 2023, Volume: 81, Issue:4

    Topics: Aprepitant; Breast Neoplasms; Cell Proliferation; Cytokines; Female; Humans; Interleukin-6; NF-kappa B; Reactive Oxygen Species; Receptors, Neurokinin-1; Substance P; Tumor Suppressor Protein p53

2023